What the FDA Relabeling of Abacavir Means for You and Your Patient

Information for Patients⁵

November 2008

Providers can also inform the patients that they are at lower risk of a serious hypersensitivity reaction when taking abacavir, however, hypersensitivity reaction can still occur because a negative test result is not 100% predictive.

Finally, patients with unknown HLA-B*5701 status should be tested prior to reinitiating abacavir treatment, even if they tolerated abacavir previously.

< Previous Slide

Information for Patients5

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?